Clearmind Medicine Looks to Move Forward with its Novel Psychedelic MEAI- Based Alcohol Substitute
Clearmind Medicine (NASDAQ: CMND) has signed a non-binding term sheet with Dr Glitter Pty to develop and commercialize a novel MEAI-based alcohol substitute using Dr Glitter's ActivCrystal™ technology. The collaboration aims to create a product that replicates alcohol's sensations without health risks or hangovers.
The ActivCrystal™ format consists of tasteless, odorless crystals made from natural ingredients that can be sprinkled on meals. Users will be able to adjust dosage individually by sprinkling the MEAI-based alternative into beverages or food. This partnership represents a strategic move in Clearmind's efforts to bring MEAI to global markets as a solution to combat alcohol misuse.
Clearmind Medicine (NASDAQ: CMND) ha firmato un accordo non vincolante con Dr Glitter Pty per sviluppare e commercializzare un nuovo sostituto dell'alcol a base di MEAI utilizzando la tecnologia ActivCrystal™ di Dr Glitter. La collaborazione mira a creare un prodotto che replica le sensazioni dell'alcol senza rischi per la salute o postumi di sbornia.
Il formato ActivCrystal™ consiste in cristalli insapori e inodori realizzati con ingredienti naturali che possono essere cosparsi sui pasti. Gli utenti potranno regolare il dosaggio individualmente aggiungendo l'alternativa a base di MEAI nelle bevande o nei cibi. Questa partnership rappresenta una mossa strategica negli sforzi di Clearmind per portare il MEAI nei mercati globali come soluzione per combattere l'abuso di alcol.
Clearmind Medicine (NASDAQ: CMND) ha firmado un acuerdo no vinculante con Dr Glitter Pty para desarrollar y comercializar un novedoso sustituto del alcohol basado en MEAI utilizando la tecnología ActivCrystal™ de Dr Glitter. La colaboración busca crear un producto que replique las sensaciones del alcohol sin riesgos para la salud ni resacas.
El formato ActivCrystal™ consiste en cristales insípidos e inodoros elaborados con ingredientes naturales que se pueden espolvorear sobre las comidas. Los usuarios podrán ajustar la dosis de manera individual añadiendo la alternativa a base de MEAI a las bebidas o alimentos. Esta asociación representa un movimiento estratégico en los esfuerzos de Clearmind para llevar el MEAI a los mercados globales como solución para combatir el abuso del alcohol.
Clearmind Medicine (NASDAQ: CMND)는 Dr Glitter Pty와 함께 Dr Glitter의 ActivCrystal™ 기술을 사용하여 MEAI 기반의 새로운 알코올 대체 물질을 개발하고 상용화하기 위한 비구속적 조건 합의서를 체결했습니다. 이 협력의 목적은 건강 위험이나 숙취 없이 알코올의 감각을 모방하는 제품을 만드는 것입니다.
ActivCrystal™ 포맷은 자연 성분으로 만들어진 맛과 냄새가 없는 크리스탈로 식사에 뿌릴 수 있습니다. 사용자들은 음료나 음식에 MEAI 기반 대체물을 뿌려 개인별로 복용량을 조절할 수 있습니다. 이 파트너십은 Clearmind가 알코올 남용 문제를 해결하기 위해 MEAI를 세계 시장에 도입하기 위한 전략적 움직임을 나타냅니다.
Clearmind Medicine (NASDAQ: CMND) a signé une feuille de conditions non contraignante avec Dr Glitter Pty pour développer et commercialiser un nouveau substitut à l'alcool à base de MEAI utilisant la technologie ActivCrystal™ de Dr Glitter. Cette collaboration vise à créer un produit qui réplique les sensations de l'alcool sans risques pour la santé ni gueules de bois.
Le format ActivCrystal™ consiste en des cristaux sans goût et sans odeur fabriqués à partir d'ingrédients naturels qui peuvent être saupoudrés sur les repas. Les utilisateurs pourront ajuster la posologie individuellement en ajoutant l'alternative à base de MEAI dans leurs boissons ou aliments. Ce partenariat représente un mouvement stratégique dans les efforts de Clearmind pour introduire le MEAI sur les marchés mondiaux comme solution pour lutter contre l'abus d'alcool.
Clearmind Medicine (NASDAQ: CMND) hat ein unverbindliches Term Sheet mit Dr Glitter Pty unterzeichnet, um ein neuartiges, MEAI-basiertes alkoholisches Ersatzprodukt mit der ActivCrystal™-Technologie von Dr Glitter zu entwickeln und zu vermarkten. Die Zusammenarbeit zielt darauf ab, ein Produkt zu schaffen, das die Empfindungen von Alkohol ohne Gesundheitsrisiken oder Kater nachahmt.
Das ActivCrystal™-Format besteht aus geschmacklosen und geruchlosen Kristallen, die aus natürlichen Zutaten hergestellt werden und über Mahlzeiten gestreut werden können. Benutzer werden in der Lage sein, die Dosis individuell anzupassen, indem sie die MEAI-basierte Alternative in Getränke oder Lebensmittel streuen. Diese Partnerschaft stellt einen strategischen Schritt in Clearminds Bemühungen dar, MEAI als Lösung zur Bekämpfung des Alkoholmissbrauchs auf die globalen Märkte zu bringen.
- Strategic partnership to develop innovative alcohol alternative delivery system
- Potential expansion into consumer market with MEAI-based product
- Flexible dosing capability through ActivCrystal™ technology
- Agreement is non-binding and preliminary
- No definitive timeline provided for product development
- Commercial viability and regulatory approval uncertain
Insights
The non-binding term sheet with Dr Glitter Pty represents an early-stage development agreement without immediate financial impact. While the ActivCrystal™ technology offers an innovative delivery method for MEAI, several critical factors remain undefined: commercialization timeline, regulatory pathway and financial terms. The lack of binding commitments and concrete development milestones makes this announcement primarily aspirational rather than materially significant.
The alcohol substitute market presents substantial potential, with the global non-alcoholic beverage market projected to reach
For a micro-cap company with a market value of
Company recently signed a non-binding term sheet with Dr Glitter Pty Ltd for mutual development in ActivCrystal™ Format
Vancouver, Canada, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, recently announced that it signed a non-binding term sheet with Dr. Glitter Pty Ltd, a health technology company that has developed ActivCrystal™ technology, a world-first oral delivery format that encapsulates active ingredients in crystals that are tasteless, odorless, made from natural ingredients, and designed to be sprinkled on meals. The two companies plan to collaborate on the development and commercialization of Clearmind’s proprietary MEAI-based alcohol substitute and Dr Glitter Pty Ltd’s proprietary ActivCrystal™ technology. The term sheet outlines preliminary terms that, upon the mutual agreement of the parties, will be memorialized in a definitive agreement that sets forth a framework for advancing Clearmind and Dr Glitter Pty Ltd’s groundbreaking innovations.
As recently announced, under the terms of the term sheet, upon the execution of the definitive agreement, the parties will work together to develop MEAI-based alcohol alternative aimed to naturally replicate the known sensations from drinking alcohol without the associated health risks or hangover. In ActivCrystal™ format, Clearmind’s MEAI-based alcohol alternative may be sprinkled into users’ choice of beverage or food, and dosage may be varied by users individually. This collaboration has the potential to mark an important milestone in Clearmind’s strategy to bring MEAI to global markets, addressing the urgent need for innovative solutions to combat alcohol misuse - a major contributor to countless annual deaths worldwide.
“We are thrilled to partner with Dr Glitter to advance the development of MEAI as a safe alternative to alcohol,” said Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine. “In parallel to advancing our clinical program with MEAI, we are actively developing our alcohol alternative product, designed to provide some of the enjoyable sensations and experiences associated with alcohol, without the alcohol itself. By offering a solution that adults can enjoy without the harmful effects of alcohol, we aim to transform the landscape of social drinking. We believe that partnering with innovative companies in this field is the right approach to drive thi change forward.”
About Clearmind Medicine Inc.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families including 29 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”
For further information visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
About Dr Glitter Pty Ltd
Dr Glitter Pty Ltd is a health technology company that has developed ActivCrystal™ technology, a world-first oral delivery format that encapsulates active ingredients in crystals that are tasteless, odourless, made from natural ingredients, and designed to be sprinkled on meals.
The Company has submitted its international patent application for the use cases, manufacturing processes, and compositions of ActivCrystals™. The product format has been commercialised under the Dr Glitter™ brand, and has extensive potential applications in dietary supplements, pet supplements, therapeutic drugs, and in geriatric and paediatric medicine. The company also intends to license its product format to brands and manufacturers globally.
For further information, please contact info@activcrystal.com
To learn more about the Dr Glitter™ brand, please visit www.drglitter.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the execution of definitive agreements with Dr. Glitter PTY Ltd., the potential collaboration and partnership with Dr. Glitter PTY Ltd., its strategy to bring MEAI to global markets, its aims to transform the landscape of social drinking and its belief that that partnering with innovative companies in the alcohol alternative and substitute market is the right approach to change the face of social drinking. The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2023 filed with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ
What is the purpose of Clearmind Medicine's (CMND) partnership with Dr Glitter?
How will CMND's MEAI-based alcohol alternative be administered?
What is the current status of CMND's agreement with Dr Glitter?
What market problem is CMND's MEAI-based alcohol alternative targeting?
